2227 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for multifactorial diseases Animal model for diseases of the immune system
GENETICALLY MODIFIED T CELL RECEPTOR MICE
#2Genetically Modified Mice and Engraftment
#3MOUSE MODELS OF CYTOKINE RELEASE SYNDROME
#4GENETICALLY MODIFIED MICE COMPRISING HUMANIZED CELLULAR IMMUNE SYSTEM COMPONENTS WITH IMPROVED DIVERSITY OF TCRB REPERTOIRE
#5Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
#6NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE
#7COMPOSITION
#8HUMANIZED MOUSE MODELS FOR ASSESSING IMMUNE CELL THERAPY
#9GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
#10Genetically Modified Non-Human Animals And Methods Of Use Thereof
#11LOW AFFINITY FcyR DEFICIENT MICE
#12COMPOSITION FOR TREATING OR PREVENTING IMMUNOLOGICAL ABNORMAL INFLAMMATORY DISEASES
#13METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS
#14NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE
#15Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant
#16METHOD AND USE OF A TRANSGENIC MOUSE LINE
#17SGRNA AND CONSTRUCTING DUAL PIG MODEL OF SEVERE IMMUNODEFICIENCY AND LIVER INJURY AND USE THEREOF
#18GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)
#19REGULATORS OF B CELL-MEDIATED IMMUNOSUPPRESSION
#20MODELS AND METHODS FOR RAPID SCREENING OF THE EFFICACY OF IMMUNOREGULATING DRUGS
#21METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME
#22JAK3 GENE-MUTATED, SEVERE COMBINED IMMUNODEFICIENCY ANIMAL MODEL AND CONSTRUCTION METHOD THEREFOR
#23NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE
#24MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT
#25TRANSGENIC MOUSE MODEL EXPRESSING HUMAN HLA-A201 RESTRICTION GENE
#26NON-HUMAN ANIMALS HAVING HUMANIZED FC-GAMMA RECEPTORS
#27GENETICALLY MODIFIED NON-HUMAN ANIMAL EXPRESSING A B2M/FCRN FUSION PROTEIN
#28HUMANIZED IL-15 ANIMALS
#29GRNA FOR KNOCKING OUT PIG XENOANTIGEN GENE, AND APPLICATION THEREOF
#30PRIMATIZED RODENT
#31GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47
#32GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMAN OR CHIMERIC THPO
#33GENETICALLY MODIFIED T CELL RECEPTOR MICE
#34GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
#35Mouse model of myocarditits
#36Genetically Modified Non-Human Animals and Methods of Use Thereof
#37GENETICALLY MODIFIED MICE COMPRISING HUMANIZED CELLULAR IMMUNE SYSTEM COMPONENTS WITH IMPROVED DIVERSITY OF TCRB REPERTOIRE
#38TRANSGENIC SWINE, METHODS OF MAKING AND USES THEREOF, AND METHODS OF MAKING HUMAN IMMUNE SYSTEM MICE
#39GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33
#40Humanized mouse models for assessing immune cell therapy
#41MURINE MODEL OF FETAL/NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
#42NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE
#43Genetically modified rat models for severe combined immunodeficiency (SCID)
#44Compositions for treating pathological calcification conditions, and methods using same
#45NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#46NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#47A GENETIC MOUSE MODEL OF AUTOIMMUNE ADVERSE EVENTS AND IMMUNE CHECKPOINT BLOCKADE THERAPY
#48NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEX
#49Conditioning regimens and methods for inducing mixed chimerism
#50Genetically Modified Mice and Engraftment
#51Genetically modified rat models for severe combined immunodeficiency (SCID)
#52Genetically modified non-human animals and methods of use thereof
#53Methods of using humanized FCγR mice to assay Fc regions
#54Mouse having a humanized B-cell activating factor gene
#55Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
#56IMMUNODEFICIENT MOUSE
#57Non-human animals having a humanized signal-regulatory protein gene
#58PRODUCTION METHOD FOR ANIMAL MODELS WITH DISEASE ASSOCIATED PHENOTYPES
#59NON-HUMAN ANIMALS HAVING A HUMANIZED A PROLIFERATION-INDUCING LIGAND GENE
#60VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#61Murine model of fetal/neonatal alloimmune thrombocytopenia
#62strain inducing inflammation in liver
#63strain inducing inflammation in liver
#64GENETICALLY MODIFIED T CELL RECEPTOR MICE
#65IMMUNORECEPTOR MODULATION FOR TREATING CANCER AND VIRAL INFECTIONS
#66In vitro immune synapse system and method of in vitro evaluating immune response using the same
#67GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX ANIMALS
#68Genetically modified non-human animals and methods relating to complement dependent cytotoxicity
#69Methods and compositions for the targeted modification of a genome
#70Non-human animals having humanized Fc-gamma receptors
#71Methods for treating pseudoxanthoma elasticum (PXE)
#72Chimeric mouse comprising stably transplanted bat cells
#73IN VITRO IMMUNE SYNAPSE SYSTEM AND METHOD OF IN VITRO EVALUATING IMMUNE RESPONSE USING THE SAME
#74Non-human animals having a humanized signal-regulatory protein gene
#75Humanized IL-15 animals
#76METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS
#77Compositions for treating pathological calcification conditions, and methods using same
#78Ungulates with genetically modified immune systems
#79Genetically modified non-human animals and methods of use thereof
#80Humanized low affinity FCγR mouse cells
#81Anti-NRP1 antibody screening method
#82THERAPIES BASED ON CONTROL OF REGULATORY T CELL STABILITY AND FUNCTION VIA A NEUROPILIN-1:SEMAPHORIN AXIS
#83Fumarylacetoacetate hydrolase (FAH)-deficient and immunodeficient rats and uses thereof
#84HUMANIZED IL-7 RODENTS
#85KLEBSIELLA PNEUMONIAE STRAIN THAT INDUCES INFLAMMATION IN THE LIVER
#86Genetically modified mice and engraftment
#87ANIMAL MODELS FOR PSORIASIS AND SCREENING METHODS
#88Construction Method for Immunodeficient Rat Model
#89Compositions for treating pathological calcification conditions, and methods using same
#90Methods and compositions for modifying a targeted locus
#91Test method
#92Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
#93Non-human animals having a humanized B-cell activating factor gene
#94Non-human animals having a humanized signal-regulatory protein gene
#95Methods and compositions for the targeted modification of a mouse ES cell genome
#96Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
#97Non-human animals expressing humanized C1Q complex
#98Genetically modified non-human animals and methods of use thereof
#99HUMANIZED MOUSE MODEL
#100Humanized IL-7 rodents
#101INTERCELLULAR LABELING OF LIGAND-RECEPTOR INTERACTIONS
#102Conditioning regimens and methods for inducing mixed chimerism
#103Genetically modified rat models for severe combined immunodeficiency (SCID)
#104Genetically modified major histocompatibility complex animals
#105Method for generating a humanized transgenic mouse comprising a human APRIL gene
#106Non-HLA matched humanized NSG mouse model with patient-derived xenograft
#107Genetically modified non-human animals and methods relating to complement dependent cytotoxicity
#108Non-human animals having a humanized signal-regulatory protein gene
#109Humanized IL-15 animals
#110METHODS OF CHARACTERIZING E-SYT2 INHIBITORS, E-SYT2 INHIBITORS, AND METHODS OF USE
#111Compositions for treating pathological calcification conditions, and methods using same
#112Compositions for treating pathological calcification conditions, and methods using same
#113Compositions for treating pathological calcification conditions, methods, and host cells using the same
#114Genetically Modified Non-Human Animals And Methods Of Use Thereof
#115Humanized FcγR mice
#116Compositions for treating pathological calcification conditions, and methods using same
#117Compositions for treating pathological calcification conditions, and methods using same
#118Humanized IL-7 rodents
#119Non-human animals having a humanized signal-regulatory protein gene
#120Polynucleotide encoding IL-35 receptor
#121Methods and compositions for modifying a targeted locus
#122Non-human animals having a humanized B-cell activating factor gene
#123ANIMAL MODEL FOR STUDYING COMPLEX HUMAN DISEASES
#124Ungulates with Genetically Modified Immune Systems
#125Genetically modified mice and engraftment
#126Genetically modified major histocompatibility complex animals
#127GENETICALLY MODIFIED NON-HUMAN MAMMALS HAVING MODIFIED LIVER CELLS AND/OR TISSUE AND METHODS OF MAKING SAME
#128NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER
#129Non-human animals having humanized Fc-gamma receptors
#130Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
#131Humanized IL-7 rodents
#132Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#133Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#134Non-human animals having a humanized signal-regulatory protein gene
#135Methods for treating disorders that involve immunoglobulin A
#136Interleukin 2 receptor gamma gene targeting vector, production of immune cell-deficient transgenic cloned mini pig having vector introduced therein, preparation method therefor and use thereof
#137Recombination activating gene 2 gene targeting vector, production of SCID-like miniature pigs by TALEN-mediated gene targeting and use thereof
#138Genetically modified non-human animals and methods relating to innate immune system response detection
#139Non-human animals having a disruption in a C9ORF72 locus
#140Animal models for evaluating pharmaceutical compounds
#141Compositions and methods for treating autoimmune and inflammatory diseases
#142GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)
#143Gene therapy to prevent reactions to allergens
#144Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction
#145Immunocompromised ungulates
#146Fumarylacetoacetate hydrolase (Fah)-deficient and immunodeficient rats and uses thereof
#147HLA class I-expressing non-human animal
#148T cell receptors that are specific to a fluorescent protein, transgenic animals and methods of their making, isolated T cells, and methods of use
#149HUMAN-INDUCED PLURIPOTENT STEM CELLS, AND METHOD FOR PREPARING ANIMAL IN WHICH HUMAN IMMUNE SYSTEM IS EXPRESSED, BY USING SAME
#150THERAPEUTIC PARASITE PREPARATION AND METHODS OF MAKING AND USING
#151Intercellular labeling of ligand-receptor interactions
#152Non-human animals having a humanized signal-regulatory protein gene
#153Genetically modified T cell receptor mice
#154Methods and compositions for modifying a targeted locus
#155Fibrotic non-human animal, and use thereof
#156Low affinity FCGR deficient mice
#157Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
#158Non-human animals having humanized Fc-gamma receptors
#159Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
#160METHODS AND COMPOSITIONS FOR TREATMENT OF TH2-MEDIATED AND TH17-MEDIATED DISEASES
#161Gene knock-in non-human animal
#162Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#163Genetic test and genetic basis for SCID in pigs
#164Genetically modified non-human animals and methods of use thereof
#165Methods and compositions for the targeted modification of a mouse genome
#166Non-human animals having a humanized a proliferation-inducing ligand gene
#167Non-human animals having a humanized B-cell activating factor gene
#168Humanized IL-15 animals
#169Genetically modified non-human animals and methods relating to innate immune system response detection
#170Non-human animals having a humanized signal-regulatory protein gene
#171Non-human animals having a humanized signal-regulatory protein gene
#172Humanized IL-7 rodents
#173TL1A model of inflammation fibrosis and autoimmunity
#174Isolated cells from humanized FcγR mice
#175Long term disease modification using immunostimulatory oligonucleotides
#176RAB6KIFL/KIF20A epitope peptide and vaccines containing the same
#177Soluble protein CD5 or CD6 for the treatment of cancer or tumor or for use as an adjuvant
#178Low affinity FCGR deficient mice
#179Humanized Fc gamma R mice
#180Generation of autologous T-cells in mice
#181Genetically modified mice and engraftment
#182Humanized IL-7 rodents
#183Methods for treating disorders that involve immunoglobulin A
#184Hairless NOD scid mouse
#185METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF THE INTERLEUKIN-35 RECEPTOR COMPLEX
#186Methods and uses of TIE2 binding and/or activating agents
#187Genetically modified mice having humanized TCR variable genes
#188CD4 T-cells and CD8zeta cells involved in mammalian host response to epithelial cell infections and uses thereof
#189Genetically modified mice and engraftment
#190Genetically modified mice and engraftment
#191T cell receptors specific for immunodominant CTL epitopes of HCV
#192METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF THE INTERLEUKIN-35 RECEPTOR COMPLEX
#193STROMAL INTERACTING MOLECULE KNOCKOUT MOUSE AND USES THEREOF
#194Low affinity FcγR deficient mice
#195Transgenic mice expressing human toll-like receptor 8
#196Composition comprising rna derived from lactic acid bacterium as effective component
#197ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
#198Hyper IgE Animal Model with Enhanced Immunoglobulin Heavy Chain Class Switching to C-epsilon
#199Nucleic acid encoding apoptotic anti-IgE antibodies
#200Methods of using apoptotic anti-IGE antibodies
#201Genetically modified rat models for severe combined immunodeficiency (SCID)
#202Apoptotic anti-IgE antibodies
#203TRANSGENIC ANIMALS EXPRESSING HUMAN IGE-M1'
#204Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction
#205Immunocompromised Ungulates
#206TL1A model of inflammation fibrosis and autoimmunity
#207Immunoadjuvant composition and use thereof
#208RAB6KIFL/KIF20A epitope peptide and vaccines containing the same
#209Humanized FcgR mice
#210Genetically modified mice and engraftment
#211Humanized FcγR mice
#212Transgenic animal with monocyte chemotactic protein 1 promoter
#213METHODS AND COMPOSITIONS FOR TREATING FUS1 RELATED DISORDERS
#214Long term disease modification using immunostimulatory oligonucleotides
#215Transgenic non-human animal and methods for stem cell engraftment
#216Ultra-small RNAs as toll-like receptor-3 antagonists
#217Animal model, and products and methods useful for the production thereof
#218IMAGEABLE RODENT MODEL OF ASTHMA
#219GENOME EDITING OF IMMUNODEFICIENCY GENES IN ANIMALS
#220GENOME EDITING OF ABC TRANSPORTERS
#221Method of identifying a compound for preventing and/or treating an autoimmune disease
#222STROMAL INTERACTING MOLECULE KNOCKOUT MOUSE AND USES THEREOF
#223METHODS OF TREATMENT USING IL-17E ANTAGONISTS
#224SHIP-deficiency to increase megakaryocyte progenitor production
#225GRP78 AND TUMOR ANGIOGENESIS
#226METHOD AND COMPOSITIONS FOR MODULATING TH17 CELL DEVELOPMENT
#227Reduction of graft-versus-host disease by modulation of SHIP activity
#228Evaluation method and screening method for substance having action of activating/suppressing innate immunity, agent and food product for activating/suppressing innate immune mechanism and method for producing the same
#229Immunocompetent xenograft model
#230Ungulates with genetically modified immune systems
#231THERAPEUTIC USES OF TIM-3 MODULATORS
#232IMMUNODEFICIENT MICE TRANSGENIC FOR HLA CLASS I AND HLA CLASS II MOLECULES AND THEIR USES
#233Genetically modified mice as predictors of immune response
#234Detection/Measurement Of Malaria Infection Disease Utilizing Natural Immunity By Hemozoin Induction, Screening Of Preventative Or Therapeutic Medicine For Malaria Infection Disease, And Regulation Of Natural Immunity Induction
#235Apoptotic anti-IgE antibodies
#236Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
#237Control of NK cell function and survival by modulation of SHIP activity
#238Ungulates with genetically modified immune systems
#239Methods for use of TSLP and agonists and antagonists thereof
#240IL-17 like molecules and uses thereof
#241Methods for use of TSLP and agonists and antagonists thereof
#242Compositions and methods for the treatment and diagnosis of immune disorders
#243IL-17 like molecules and uses thereof
#244Il-17 like molecules and uses thereof
#245IL-17 like molecules and uses thereof